<DOC>
	<DOCNO>NCT01693679</DOCNO>
	<brief_summary>• To estimate renoprotective efficacy Telbivudine treat patient HBV-related liver cirrhosis .</brief_summary>
	<brief_title>Telbivudine Renoprotective Effect Patients With HBV-related Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Subjects eligible enrolment study must meet following criterion : Aged 1875 year ( inclusive ) . Male female . Subjects positive HBsAg 6 month antiHBs negative regardless HBeAg status , HBV DNA ≥2×103 IU/ml Subjects HBVrelated liver cirrhosis , include compensate cirrhosis decompensated , ChildPugh A B . The ablility understand sign write informed consent prior study related procedure comply requirement study . Subjects meet follow criterion must enrol study Subjects nonHBV cirrhosis Coinfection HAV/HCV/HDV/ HIV Subjects take nucleoside within 6 month Kidney injury due nonHBV factor Inability comply study requirement determine study investigator Patients low GFR , may need dialysis renal transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Tebivudine eGFR non-Tebivudine</keyword>
</DOC>